Center of Internal Medicine II, University Hospital Brandenburg, Brandenburg Medical School, Brandenburg, Germany.
Department of Anatomy and Experimental Morphology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J Gastroenterol Hepatol. 2018 Jul;33(7):1353-1356. doi: 10.1111/jgh.14082. Epub 2018 Mar 12.
An outbreak of Shiga toxin 2 (Stx2) producing enterohemorrhagic and enteroaggregative Escherichia coli O104:H4 infection in May 2011 in Germany caused enterocolitis and an unprecedented high 22% rate of hemolytic uremic syndrome (HUS). We hypothesized that anti-Stx2 IgM or IgG titers might predict HUS development.
Thirty-two patients infected with enterohemorrhagic Escherichia coli O104:H4 (HUS: n = 23; non-HUS: n = 9) were retrospectively screened for anti-Stx2 IgM/IgG and matched with clinical data regarding HUS development, fever, superinfection, dialysis, neurological symptoms, intensive care, antibiotic treatment, and plasmapheresis.
Only HUS patients showed a prominent Stx2-specific humoral response in the early acute phase. Despite a strong trend towards prediction of HUS development, statistical analysis revealed no significant correlation between high IgM/IgG titers and further key clinical parameters such as fever, superinfection, neurological symptoms, antibiotic treatment, and plasmapheresis.
Anti-Stx2 antibodies seem to accompany or even precede HUS development.
2011 年 5 月,德国暴发了由产志贺毒素 2(Stx2)的肠出血性和肠聚集性大肠杆菌 O104:H4 引起的感染,导致了肠炎和史无前例的 22%的溶血性尿毒症综合征(HUS)发病率。我们假设抗 Stx2 IgM 或 IgG 滴度可能预测 HUS 的发生。
对 32 例感染肠出血性大肠杆菌 O104:H4(HUS:n=23;非 HUS:n=9)的患者进行了回顾性筛选,以检测抗 Stx2 IgM/IgG,并与 HUS 发展、发热、继发感染、透析、神经系统症状、重症监护、抗生素治疗和血浆置换等临床数据进行了匹配。
只有 HUS 患者在早期急性阶段表现出明显的 Stx2 特异性体液反应。尽管抗 Stx2 抗体的高滴度有预测 HUS 发展的趋势,但统计学分析显示,高 IgM/IgG 滴度与发热、继发感染、神经系统症状、抗生素治疗和血浆置换等关键临床参数之间没有显著相关性。
抗 Stx2 抗体似乎伴随着或甚至先于 HUS 的发展。